anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an ointment. The ointment comprises the following components: pseudo-ginseng, asarum and Chinese prickly ash. Pseudo-ginseng is extracted by a reflux extraction method. The technological conditions are as follows: 50% ethanol is selected; total weight is 8 times larger than weight of pseudo-ginseng; immersion time is 40 min; hot reflux is carried out twice, 2h for each time; and after recovery of ethanol, the extract is concentrated to obtain an ethanol extract. Asarum volatile oil is extracted by a steam distillation method. Chinese prickly ash volatile oil is extracted by a steam distillation method. finally, the ethanol extract, the asarum volatile oil, the Chinese prickly ash volatile oil and a matrix undergo mixing and homogenization so as to obtain the Sanxinjiao ointment. In allusion to insufficiencies in the prior art and according to clinical finding that cervical spondylopathy is mostly caused by wind cold dampness, pseudo-ginseng for promoting blood circulation to arrest pain, as arum for dispelling cold to relive pain and Chinese prickly ash for removing dampness to kill pain are used as main drugs. By a modern Chinese herbal preparation technology, the Sanxinjiao ointment is self-made. With combination of massage, the Sanxinjiao ointment achieves a good curative effect in clinically treating cervical spondylopathy.
The olecranon bursa is a pocket-like structure located at the posterior aspect of the elbow that is responsible for the smooth movement of the surrounding tissues. Frequently, it is the source of elbow pain due to an inflammation which may be caused by local injury or penetration of bacteria through the skin. This can lead to an initial acute and possibly a late chronic inflammation. Chronic inflammation may originate from systemic diseases such as gout and rheumatoid arthritis as well. The treatment of olecranon bursitis may be conservative (non-surgical) or surgical. Recently, there is more supporting evidence for the use of conservative management over surgical intervention in treating olecranon bursitis.
NCI carries out extensive research and surveillance activities that rely on self-reported dietary information from questionnaires and interviews. Although scientists have long recognized that this information contains error, considerable uncertainty remains about its structure. The interpretation of findings from NCI's nutritional epidemiology and surveillance efforts is critically dependent on the assessment of dietary measurement error. We evaluated such measurement error in the previously conducted Observing Protein and Energy Nutrition Study (OPEN) conducted in 1999 and 2000. This study, the largest study of its kind, used unbiased biomarkers of dietary intake (doubly labeled water for energy and 24-hour urinary nitrogen for protein) to assess measurement error in dietary assessment methods commonly used in epidemiology and surveillance research around the world. The landmark findings indicate that relative risk estimates in nutritional epidemiology may be severely attenuated by the use of food frequency questionnaires and that the conventional use of 24-hour dietary recalls as reference measurements may lead to severe underestimates of the extent of this attenuation. Key questions remain regarding whether these findings hold in diverse populations, for other dietary-report or physical activity instruments, across varying nutrients and food groups, and how measurement error affects relative risks in existing prospective cohorts. In light of the OPEN study findings, we would like to re-contact participants, for whom we already have a wealth of nutritional biomarker data, in order to assess the structure of measurement error with respect to two other self-reported dietary assessment instruments: the food record and a food checklist-adjusted food frequency questionnaire. Our intent is to evaluate whether these instruments might have more favorable measurement error structure than the food frequency questionnaire, thereby providing better tools for nutritional epidemiology.
FIELD: organic chemistry, biochemistry. SUBSTANCE: invention describes a new heterocyclic derivative of the general formula (I) or its pharmaceutically acceptable salts where Ar 1  means imidazolyl, pyrazolyl, 1,2,3- -triazolyl, 1,2,4-triazolyl that bound with X 1  by the ring nitrogen atom and can be optionally substituted with one or two C 1-4 -alkyls; X 1  means a direct bond or C 1-4 -alkylene; Ar 2  means phenylene optionally substituted with one or two halogen atom; X 2  means -A-X- or -X-A- where A means a direct bond or C 1-4 -alkylene and X means hydroxy- or thio-group; Ar 3  means phenylene optionally substituted with one or two substituents taken among halogen atom or cyano-group; R 1  and R 2  in common form the group of the formula -D 1 -Z-D 2 - that in common with carbon atom to which it bound forms a ring having 3-8 atoms where D 1  and D 2  mean C 1-4 -alkylene and Z means a direct bond, hydroxy-group or vinylene; D 1  and D 2  can be substituted with C 1-3 -alkyl and Y means CONR 3 R 4 ,CN,C(R 3 )=N-OR 4 ,COOR 3  or COR 3  where R 3  and R 4  each means H or C 1-4 -alkyl. Compounds of the formula (I) inhibit activity of enzyme 5-lipoxygenase and can be used for treatment or relief of inflammatory diseases, allergy and cardiovascular diseases in mammals. Invention describes also a pharmaceutical composition on the base of compounds of the formula (I) and a method of inhibition of activity of 5-lipoxygenase. EFFECT: valuable pharmacological and biochemical properties of compounds. 12 cl, 44 ex
FIELD: veterinary science. SUBSTANCE: invention relates to preparing agents for specific rabies prophylaxis in all species of agricultural and domestic animals. Fixed rabies virus is cultured in suspension culture of cells VNK-21 at 35-37 C for 96-144 h. After termination of virus reproduction polyacrylic acid or feracryl (stabilizing agents) up to concentration 0.7-1.0% are added in virus-containing suspension followed by addition of ethyleneimine dimer (inactivating agent) up to concentration 0.1-0.3%. Mixture is incubated at 35-37 C for 20-24 h and obtained vaccine is used both as a liquid and dried form. To obtain the dried preparation a liquid vaccine is dried by sublimation. EFFECT: increased specific safety, immunogenic activity, stability and harmlessness of vaccine, decreased reactivity and allergenicity. 8 cl, 2 tbl, 5 ex
OBJECTIVES: I. Compare the overall survival of patients with non-small cell lung cancer treated with paclitaxel alone or in combination with carboplatin. II. Compare the quality of life of these patients treated with these chemotherapy regimens. III. Compare the response rates and the toxic effects of the two regimens in this patient population.

OUTLINE: This is a randomized study. Patients are stratified according to stage of disease (stage IIIB vs stage IV vs recurrent or progressive after surgery and/or radiotherapy), performance status (0-1 vs 2), and age (under 70 vs 70 and over). Patients are randomized to one of two treatment arms. Arm I receives paclitaxel IV over 3 hours on day 1 of each course. Arm II receives paclitaxel as in Arm I, followed by carboplatin IV over 1 hour. Treatment is repeated every 21 days for 6 courses in the absence of tumor progression or unacceptable toxicity. Quality of life assessments are conducted before treatment and at 2, 6, 9, and 12 months. Patients are followed every 3 months for 2 years, then every 6 months until disease progression or death.
A South Asian male in his early 60s presented with acute-onset dyspnoea on postoperative day 4 after undergoing middle hepatic vein sacrificing partial liver resection for epithelioid angiomyolipoma. The patient's SpO2 on presentation was 65% in standing position which improved to 90% in left lateral decubitus. He was suspected of having platypnea-orthodeoxia syndrome (POS) which was confirmed on echocardiogram with microbubble contrast showing a large intracardiac right-to-left shunt. The patient was taken up for transcatheter closure of patent foramen ovale (PFO). A 30 mm Amplatzer PFO Occluder was deployed across the PFO which reduced the intracardiac shunt resulting in an improved arterial saturation as well as immediate relief of patient's symptoms. This case illustrates the importance of suspecting and recognising POS clinically as well as the efficacy of transcatheter closure of PFO in such cases leading to resolution of hypoxaemia in a short span of time.
The invention comprises salts of polybasic acids with homatropine and with one or more morphine alkaloids or their narcotic derivatives having the morphine ring-system.  The salts are made by dissolving the components in a common solvent (or separately and then mixing) and isolating the product by evaporation or precipitation. Alternatively they may be prepared by double decomposition, e.g. from a barium salt of the acid and the sulphate of the base.  Examples show the production of dihydrohydroxycodeinone homatropine terephthalate, dihydromorphinone homatropine citrate, morphine homatropine malonate, dihydrocodeinone homatropine tartrate, codeine homatropine succinate, ethylmorphine homatropine aconitate, dihydrocodeine homatropine phthalate and codeine homatropine fumarate.  Other specified acids are camphoric, phenoldisulphonic, benzenetrisulphonic, salicyldisulphonic, saccharic, sulphuric, sulphurous and phosphoric.ALSO:Narcotic compositions contain a salt of a polybasic acid with homatropine and with one or more morphine alkaloids or their narcotic derivatives having the morphine ring-system.  Preferably such salt is mixed with a larger amount of a simple salt of the narcotic base.  The compositions may be in the form of tablets, capsules, solutions or suppositories and may be administered by injection, per oz or into the rectum.  The usual binders, diluents, lubricating agents and stabilizers may be present. As an example a mixture of dihydrohydroxycodeinone homatropine tetaphthalate, dihydrohydroxycodeinone hydrochloride, lactose, starch, dextrin, a dyestuff and water is granulated with methanol, and the talc and starch added; the mixture is converted into tablets. Two or more narcotic bases may be present in the composition.  Other specified double salts are dihydromorphinone homatropine citrate, morphine homatropine malonate, dihydrocodeinone homatropine tartrate, codeine homatropine succinate, ethylmorphine homatropine aconitate, dihydrocodeine homatropine phthalate and codeine homatropine fumarate.  The salts may also be derived from camphoric, phenoldisulphonic, benzenetrisulphonic, salicyldisulphonic, saccharic, sulphuric, sulphurous or phosphoric acid.
Patients will be randomized at their pre-surgical consultation. Patients will undergo a physical therapy evaluation prior to surgery and at 4 and 8 weeks post-op. Their preoperative visits will be as close to 4 weeks before surgery as possible but given the urgency of some of these surgeries and diagnoses, treatment will not be delayed to complete the components of this study. The patient will also be asked to complete a quality of life assessment at the beginning and end of the study as well as an anonymous survey at the conclusion of the study evaluating her satisfaction with the experiment.
The present invention is a technique and apparatus for providing preferential enhancement of an artery of interest relative to adjacent veins and background tissue by correlating the collection of a predetermined portion of data of a magnetic resonance contrast image during the arterial phase of the magnetic resonance contrast enhancement. The arterial phase of the contrast enhancement may be described as a period of a maximum, substantially elevated, or elevated contrast concentration in the artery of interest relative to adjacent veins. The present invention includes a detection system for monitoring and detecting the arrival of the contrast agent in the artery and tissues of interest. When the concentration of contrast agent in the artery of the region of interest is maximum, substantially elevated or elevated (e.g., about 20-50% greater than the response of the region of interest to a series of magnetic resonance pulses before administration of a magnetic resonance contrast agent), a predetermined portion of the magnetic resonance image data (e.g., data which is representative of the center of k-space) may be acquired. Thus, the present invention facilitates synchronization between collecting the central portion of k-space image data with the arterial phase of contrast enhancement. The center of k-space corresponds to the lowest spatial frequency data which dominates image contrast.
The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group B, blood pressure is controlled by Candesartan plus Cilnidipine. If blood pressure is not lowered by Candesartan plus Cilnidipine alone, another antihypertensive agents except CCB and ACEI are allowable.
Human saliva is used as a non-invasive source instead of invasive blood serum plasma for detection and assay of endogenously present proteins; nerve growth factor (NGF), myoglobin, Insulin, adenosine deaminase (ADA), including immunoglobulin E (IgE). It was discovered that people having high levels of IgE, show high levels in comparison to the normal controls of NGF, myoglobin, insulin and ADA, disrupting the homeostasis for these proteins. Oral administration of a synthetic peptide LT-10 disclosed in U.S. Pat. No. 5,576,297 having sequence L K A M D P T P P L reduces free IgE level in humans and brings other proteins int homeostasis, for example, NGF, myoglobin, insulin and ADA and possibly other proteins and cytokines. Composition of synthetic LT-10 is advocated as a treatment for IgE implicated disorders such as asthma, depression and various types of autoimmune diseases, such as erythematosus (SLE); Rheumatoid arthritis Sjogren's syndrome; Reiter's syndrome; Diabetes mellitus (insulin-dependent); Graves' disease; Addison's disease; Hodgkin's disease, etc.
PCT No. PCT/US90/00727 Sec. 371 Date Aug. 6, 1991 Sec. 102(e) Date Aug. 6, 1991 PCT Filed Feb. 8, 1990.A two phase adhesive matrix for use in an electrically powered iontophoretic delivery device is provided. The adhesive matrix comprises an adhesive hydrophobic polymer phase and about 15 to 60 wt % on a dry weight basis of a hydrophilic polymer phase distributed through the hydrophobic polymer phase. The hydrophilic phase forms upon hydration an interconnecting network of aqueous pathways for passage of the agent through the adhesive. The adhesive can be used to adhere an electrode assembly of an iontophoretic delivery device to a body surface such as skin or a mucosal membrane. Alternatively, the adhesive can be used to adhere together two or more elements of an iontophoretic delivery device.
A marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease and cancer, the method of detection of the marker and a diagnosis kit of the diseases are provided. Additionally, therapeutic agents of the diseases are provided.   The expression of KIAA1036 is enhanced in ovarian cancer and large bowel cancer and KIAA1036 expresses in umbilical vein endothelial cell and inhibits DNA synthesis in the cells, cell migrating and lumen formation. Therefore KIAA1036 is useful as a marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease or cancer. Additionally, KIAA1036 is useful for screening of agonists, antagonists, DNA synthesis inhibitors, cell migrating inhibitors and neovascular inhibitors. The substances obtained by the screening, KIAA1036 and the antibodies are useful as therapeutic agents the above disease.
ArmA receives chemotherapy on D1 and immunotherapy on D8 of a 28-day cycle for the first 2cycles. After the first 2cycles, patients on Arm A and Arm B will be administered chemotherapy and immunotherapy on D1 of a 21day cycle for cycles 3 and 4. After 4cycles of chemo-immunotherapy, patients receive maintenance therapy with durvalumab and pemetrexed until treatment discontinuation. Maintenance therapy is administered on D1 of a 21day cycle.
The prognosis for patients who achieve a pathologic complete response in bladder cancer is excellent, but the association between their prognosis and the tumor microenvironment is unclear. We investigated the tumor immune microenvironment of those with pathological complete response after platinum-based neoadjuvant chemotherapy for cT2-4aN0M0 bladder cancer using multiplex fluorescence immunohistochemistry. Our retrospective study included 12 patients with pathological complete response who underwent radical cystectomy following neoadjuvant chemotherapy for cT2-4aN0M0 muscle-invasive bladder cancer. We assessed the density of several immune cell types in pretreatment and posttreatment tissues via multiplex fluorescence immunohistochemical analysis. The median age was 67 years; 10 patients were male. Nine (75%) and 3 (25%) patients were cT2 and cT3, respectively. The 5-year progression-free and overall survivals were 90% and 100%, respectively. The densities of regulatory T cells (Treg; CD3+CD4+FoxP3+ cell) were significantly decreased and almost disappeared in the tumor microenvironment of posttreatment tissue compared with pretreatment tissue. Other immune cells, such as effector T cells or M2 macrophages, were not significantly changed between posttreatment and pretreatment tissues. In pathological complete response, Tregs in the tumor immune microenvironment were significantly decreased after platinum-based chemotherapy for muscle-invasive bladder cancer. The temporary arresting of immune response in the tumor microenvironment may reflect a favorable prognosis due to the decrease of Tregs with tumor shrinkage and improve the host tumor immune response.
An apparatus for the production of encapsulated bodies employing a dropping tank for a fluid to form the cores of the encapsulated bodies and a reaction tank containing a solution capable of forming gel skins upon contact with the core material in communication therewith. Double-walled cylindrical nozzles are arranged in a lower part of the drop tank, the inner and outer walls of the double-walled cylindrical nozzles being coaxial. A pressurized air feed pipe is in communication with an upper part of the dropping tank. The peripheral walls of the reaction tank are in the form of a double-walled cylinder whose upper peripheral portion of its inner wall contains a screen. A liquid feed pipe and a capsule discharge port are provided in communication with the interior of the reaction tank through lower parts of the double-walled cylinder. A liquid discharge port also is provided in communication with an annular spacing of the double-walled cylinder through its outer wall. 
     The apparatus provides for obtaining a dispersion of encapsulated bodies without their mechanical separation from the liquid in which they are prepared.
Participants with active and progressive PsA who have responded inadequately to disease-modifying anti-rheumatic drugs will receive induction infusions of Remicade at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians. Whole observation period cannot exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in the Summary of Product Characteristics (SPC) is taken into consideration.
This experiment will use a clinical design that will collect cases in a local teaching hospital. The way of convenience sampling will gather from the irritable bowel syndrome patients. After a questionnaire, randomly to make invention and control groups. Invention and control groups are 4 weeks and 3 weeks respectively. Each time will be for 20 minutes acupuncture-like transcutaneous electrical nerve stimulation treatment. The Control group will still have normal nursing. There will be 72 patients in two groups. The measured timing will be in the second, fourth, and eighth weeks after the prediction and invention.
This is a random, open label, and parallel controled experiment. 45 patients are selected and sign consent forms, then divided into three groups. Doctors collect the basic information of patient (including age,height, mental condition, vital sign, history of disease, pharmaco-history, genotype test, and so on.) All patients receive laboratory and image examination as baseline. Then, they will give cell treatment based on the clinical protocol. Doctors have follow-up visit on 1, 2, 3, 6, and 12 months after treatment, and do efficacy evaluation.
OBJECTIVE: This study compared adults with peripheral vestibular hypofunction (VH) to healthy controls and assessed the sensitivity and specificity of the Cervical Torsion Test (CTT) and the Head-Neck Differentiation Test (HNDT). This study aimed to determine whether neck problems affected primary outcomes.
METHODS: This cross-sectional study included adults from a specialist consultation for dizziness. VH had been diagnosed with the video Head Impulse Test. Exclusion criteria were conditions following head or neck trauma and diseases of the central nervous system. The sensitivity and specificity of the index tests were calculated, and regression analyses were performed to test for contributing factors.
RESULTS: A total of 19 patients with VH and a historical cohort of 19 matched healthy controls were included. Most patients with VH (84.2%) experienced symptoms in at least 1 test component, compared to 5.2% of the control group. Of patients with VH, 78.9% had symptoms during the HNDT "en bloc" (en bloc = head and trunk rotated together), whereas only 26.3% reported symptoms during the CTT en bloc. The best discriminatory validity was found for the HNDT en bloc, with a sensitivity of 0.79 (95% CI = 0.54-0.94), a specificity of 0.86 (95% CI = 0.65-0.97), and a positive likelihood ratio of 5.79 (95% CI = 1.97-17.00). The number of symptoms of CTT "in torsion" (in torsion = trunk rotated actively with fixed head) was increased by a factor of 1.13 (95% CI = 1.01-1.27) for every additional point on the Neck Disability Index.
CONCLUSION: The CTT and HNDT can serve as non-laboratory tests for patients with dizziness. The HNDT en bloc has the best discriminatory validity, finding those with and those without VH. Symptom reproduction during torsion may help to identify when neck problems may contribute to dizziness.
IMPACT: The HNDT en bloc may be useful for ruling VH in or out in patients with dizziness. Positive CTT and HNDT in torsion components may verify the likelihood of additional neck involvement.